Skip to main content
OpenTrials
Completed

NCT Number: NCT04035824

Gastrodia and Uncaria Recipe in Treating Stage-one Hypertension: an Evidence-based Optimization Study

Gastrodia and Uncaria Recipe is a well-known effective prescription in Traditional Chinese Medicine (TCM) to treat hypertension of liver yang hyperactivity type, which manifests symptom of headache or dizziness. However, it lacks consolidated evidence by multi-center randomized controlled trials. The hypothesis of this study is that Gastrodia and Uncaria granule may have significant anti-hypertensive effect on patients with stage-one hypertension and liver-yang hyperactivity syndrome than placebo.

This study is a randomized, controlled, multi-center, double-blind clinical trial. This study aims to recruit 500 hypertension patients who 1) are untreated or taking anti-hypertensive medicine for at least two weeks and 2) have an office systolic blood pressure of 140-159 mmHg, an office diastolic blood pressure of <100 mmHg, and a 24-hour ambulatory mean systolic blood pressure of >=130 mmHg. The patients will be stratified according to center, sex, and the TCM type of liver yang hyperactivity/ liver yang non-hyperactivity, and are then randomly assigned to the treatment of Gastrodia and Uncaria granules or placebo for 2 months. The blood pressure lowering effect is evaluated by 24-hour ambulatory systolic blood pressure (primary outcome) / diastolic blood pressure, as well as by home and office blood pressures.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Hypertension Cardiovascular Diseases Vascular Diseases

Age range

18 year–80 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

Ruijin Hospital

Shanghai, Shanghai Municipality, 200025, China

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Male and female sex, aged 18-80 years.
  • Not taking anti-hypertensive drugs for at least two weeks, or taking anti-hypertensive drugs for more than two weeks.
  • Office blood pressure averages of three consecutive readings per visit, at two screening visits all meet the limits: systolic blood pressure ranges from 140 to 159 mmHg, and diastolic blood pressure <100 mmHg.
  • 24h ambulatory mean systolic blood pressure >= 130mmHg.
  • Agreed to participant, able to join follow-up and to come to hospital at each visit.
  • Signed informed consent.

Exclusion criteria

  • Secondary hypertension, confirmed or suspected.
  • Failed at ambulatory blood pressure monitoring: effective reading < 70%, or the number of awakening BP reading <20, or sleep time BP reading <7.
  • Taking drugs that must be used for other diseases but have a potential effect on blood pressure, such as males taking alpha blockers for prostatic hypertrophy.
  • Having the onset of cardiovascular and cerebrovascular diseases such as stroke, myocardial infarction or heart failure within 6 months.
  • Having a history of atrial fibrillation or frequent arrhythmia.
  • Having abnormal lab test results: liver function (ALT, AST, TBL) ≥ 2 times the upper normal limit, or serum creatinine ≥ 176umol/L, or serum potassium ≥ 5.5mmol/L.
  • Pregnant or breastfeeding (for females).
  • Complicating other diseases that are not suitable for the trial, such as thyroid disease with active medication, acute infectious diseases, chronic mental illness, and tumors.
  • Possible poor compliance with the research process.

Treatment and study plan

Gastrodia and Uncaria granule

Drug

Patients allocated to the intervention group take 10g of Gastrodia and Uncaria granule each time, twice per day, and for two months.

Placebo of Gastrodia and Uncaria granule

Drug

Patients allocated to the control group take 10g of placebo of Gastrodia and Uncaria granule each time, twice per day, and for two months. The placebo has similar appearance and smell to genuine drug but has no effective anti-hypertensive agents.

Primary outcomes

  1. Change in 24-hour ambulatory systolic blood pressure

    Time frame: 8 weeks

    The difference of change of 24h ambulatory systolic blood pressure after 8-week treatment between treatment and control group

Secondary outcomes

  1. Change in office blood pressure

    Time frame: 4 and 8 weeks

    The difference of change of office systolic and diastolic blood pressure between treatment and control group

  2. Change in 24-hour ambulatory systolic blood pressure by stratum

    Time frame: 8 weeks

    The difference of change of 24h ambulatory systolic blood pressure after 8-week treatment between liver yang hyperactivity and liver yang non-hyperactivity stratum

  3. Change in 24-hour ambulatory diastolic blood pressure, daytime and nighttime blood pressure

    Time frame: 8 weeks

    The difference of blood pressure change of 24-hour mean ambulatory diastolic, daytime and nighttime systolic and diastolic between treatment and control group.

  4. Change in home blood pressure

    Time frame: 8 weeks

    Difference of change of home systolic and diastolic blood pressure after 8-week treatment between treatment and control group.

Sponsors and collaborators

Lead sponsor

Shanghai Institute of Hypertension

Other

Collaborators

  • Ruijin Hospital
  • Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

Registry information

Official study title

Evidence-based Optimization of Gastrodia and Uncaria Recipe in Treating Stage-one Hypertension: a Multi-center, Randomized, Double-blind, Placebo Controlled Trial

Important dates

Study start
2019
Primary completion
2024
Study completion
2024
First posted
Jul 29, 2019
Registry last updated
Jan 7, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.